| 35.8 0.35 (0.99%) | 01-08 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 44.08  |
1-year : | 51.48 |
| Resists | First : | 37.74 |
Second : | 44.08 |
| Pivot price | 34.98 |
|||
| Supports | First : | 34.61 |
Second : | 32.68 |
| MAs | MA(5) : | 34.79 |
MA(20) : | 35.17 |
| MA(100) : | 32.98 |
MA(250) : | 25.48 |
|
| MACD | MACD : | -0.5 |
Signal : | -0.6 |
| %K %D | K(14,3) : | 54.8 |
D(3) : | 41.2 |
| RSI | RSI(14): 51.1 |
|||
| 52-week | High : | 42 | Low : | 14.06 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ NAMS ] has closed below upper band by 26.1%. Bollinger Bands are 43.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 36.28 - 36.42 | 36.42 - 36.56 |
| Low: | 34.73 - 34.9 | 34.9 - 35.07 |
| Close: | 35.53 - 35.79 | 35.79 - 36.04 |
NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.
Tue, 06 Jan 2026
NewAmsterdam Pharma Company N.V. (NAMS) Shares Spiked by 57% in Q3 - Yahoo Finance
Tue, 06 Jan 2026
NewAmsterdam Pharma stock price target raised to $55 by Leerink Partners - Investing.com Nigeria
Mon, 05 Jan 2026
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Mon, 05 Jan 2026
NewAmsterdam Pharma stock slides on insider sale notices — what investors watch next for NAMS - TechStock²
Tue, 16 Dec 2025
NewAmsterdam Pharma (NASDAQ:NAMS) Stock Price Expected to Rise, Stifel Nicolaus Analyst Says - MarketBeat
Fri, 05 Dec 2025
NewAmsterdam Pharma Company Grants Inducement Share Options to New Hires | NAMS Stock News - Quiver Quantitative
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 113 (M) |
| Held by Insiders | 6.248e+007 (%) |
| Held by Institutions | 0.3 (%) |
| Shares Short | 6,820 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.0272e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -15 % |
| Return on Assets (ttm) | 845.6 % |
| Return on Equity (ttm) | -20.8 % |
| Qtrly Rev. Growth | 3.524e+007 % |
| Gross Profit (p.s.) | -1976 |
| Sales Per Share | -798.8 |
| EBITDA (p.s.) | 7.048e+008 |
| Qtrly Earnings Growth | -2.1 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -144 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.05 |
| Price to Cash Flow | 0.27 |
| Dividend | 0 |
| Forward Dividend | 6.26e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|